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Background: Umeclidinium bromide (UMEC) is an inhaled long-acting muscarinic antagonist in development for
chronic obstructive pulmonary disease (COPD).
Methods: This was a multicentre, randomised, double-blind, placebo-controlled, three-way cross-over, incomplete
block study to evaluate UMEC 15.6, 31.25, 62.5, and 125 μg administered once daily (QD), and UMEC 15.6 μg and
31.25 μg administered twice daily (BID), over 7 days in patients with COPD. Tiotropium was included as an
open-label treatment arm. The primary efficacy endpoint was trough forced expiratory volume in 1 second (FEV1)
on Day 8. Secondary efficacy endpoints included weighted mean FEV1 over 0–24 hours after morning dosing on
Day 7, and serial FEV1 at each time point over 24 hours after morning dosing on Day 7. Safety and
pharmacokinetics were also examined.
Results: One hundred and sixty-three patients (mean age 59.5 years, 52% female) were randomised. Based on the
population dose–response model of trough FEV1 data, the geometric mean potency (ED50) of UMEC was 37 μg
(95% confidence interval [CI]: 18, 57) with a predicted maximum intrinsic efficacy (Emax) at trough of 0.185 L
(95% CI: 0.153, 0.218) after QD dosing. UMEC 125 μg QD demonstrated the greatest improvements in measure of
lung function compared with doses of 62.5 μg and below. UMEC 125 μg QD exhibited more consistent increases in
FEV1 from baseline across serial time points over 24 hours compared with other UMEC doses and tiotropium.
Increases in FEV1 over 0–12 hours were similar to those observed over 12–24 hours after the second dose of UMEC
was administered. UMEC was rapidly absorbed following inhaled dosing and eliminated from plasma. Adverse
events, generally mild, were highest with UMEC 125 μg QD (18%) compared with placebo (8%), tiotropium (4%)
and other UMEC doses (5–12%).
Conclusions: UMEC is a potent QD bronchodilator with geometric mean ED50 of 37 μg. A dose ordering over the
range of UMEC 15.6–125 μg QD doses was observed, with UMEC 125 μg showing the greatest improvement in
trough FEV1.
Trial registration: GlaxoSmithKline funded (clinicaltrials.gov NCT01372410; GlaxoSmithKline study number AC4115321).
Keywords: Chronic obstructive pulmonary disease (COPD), Long-acting bronchodilators, Long-acting muscarinic
antagonist (LAMA), Umeclidinium (UMEC), GSK573719* Correspondence: misba.2.beerahee@gsk.com
2Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, Stevenage
SG1 2NY, UK
Full list of author information is available at the end of the article
© 2014 Church et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Church et al. BMC Pulmonary Medicine 2014, 14:2 Page 2 of 14
http://www.biomedcentral.com/1471-2466/14/2Background
Cholinergic tone is considered the major reversible com-
ponent of airflow obstruction in patients with chronic
obstructive pulmonary disease (COPD) [1]. Receptor
antagonism by antimuscarinic agents facilitates relax-
ation of airway smooth muscle. These agents bind to
muscarinic receptor subtypes M1 and M3 localised in
airway smooth muscle and block the bronchoconstrictor
response to cholinergic nerve stimulation [2,3], thereby
improving airflow obstruction. Long-acting muscarinic
antagonists (LAMAs) have been shown to be a more
effective and convenient treatment for COPD than short-
acting bronchodilators [4].
Umeclidinium bromide (UMEC; GSK573719) is an
inhaled LAMA in development for the treatment of
COPD. Pharmacology studies have demonstrated that
single- and repeat-dose UMEC administration is well
tolerated in healthy volunteers [5] and in patients with
COPD [6,7]. Statistically significant improvements in
change from baseline in trough forced expiratory vol-
ume in 1 second (FEV1) were demonstrated compared
with placebo [6,8]. Although the dose–response curve
of UMEC from 62.5 μg to 1000 μg has been examined
over 14 [6] and 28 days [8], the response obtained over
this dosing range was relatively flat.
The current study examined the dose–response and
safety of UMEC 15.6, 31.25, 62.5, and 125 μg administered
once daily (QD), and UMEC 15.6 and 31.25 μg twice daily
(BID). A model-based approach to the assessment of
dose response has the advantage of utilising informa-
tion within and across the range of doses studied for a
more informed assessment of the drug’s dose–response
relationship [9]. Preliminary results have been presented
in abstract form [10].
Methods
Patients
Study investigators enrolled eligible patients who were
40–80 years of age, had a clinical history of COPD as de-
fined by the American Thoracic Society (ATS)/European
Respiratory society [11], were current or former cigarette
smokers with a history of cigarette smoking of ≥10 pack-
years, and had a post-salbutamol FEV1/forced vital capacity
(FVC) ratio of <0.70 and a post-salbutamol FEV1 of ≥35%
and ≤70% of predicted normal values [12,13]. Patients were
excluded if they had a current diagnosis of asthma, known
α1-antitrypsin deficiency, active lung infections, lung
cancer, any clinically significant uncontrolled disease,
or an abnormal and significant electrocardiogram (ECG)
or significantly abnormal clinical laboratory finding. Con-
comitant use of inhaled salbutamol as a rescue medication
was allowed. Inhaled corticosteroids (ICS) at a dose up to
1000 μg/day of fluticasone propionate or equivalent were
permitted, provided the dose remained stable throughoutthe treatment period. Initiation or discontinuation of ICS
or long-acting β2-agonist/ICS combinations within 30 days
prior to screening was prohibited; however, patients were
allowed to discontinue long-acting β2-agonist/ICS up to 2
days prior to screening if ICS alone was continued.
Written consent was obtained prior to the start of
study-specific procedures. The study (clinicaltrials.gov
NCT01372410; GSK study number AC4115321) was ap-
proved by the local ethics review committee (Chesapeake
IRB, Columbia, MD) and was conducted in accordance
with the Declaration of Helsinki and Good Clinical Practice
guidelines [14].
Study design and treatment
This randomised, incomplete block, three-period cross-
over, placebo-controlled study was conducted in 15 centres
in the United States from 25 July 2011 to 27 October 2011.
In accordance with the randomisation schedule, generated
using SAS and RandAll version 2.5, patients were assigned
to receive a sequence of three of eight potential treatments
for a total of three treatment periods per patient. UMEC
15.6 μg QD, 31.25 μg QD, 62.5 μg QD, 125 μg QD, 15.6 μg
BID, 31.25 μg BID, open-label tiotropium 18 μg QD, and
placebo were evaluated. UMEC and matching placebo
study medication were administered via the ELLIPTA™ dry
powder inhaler a in a double-blind fashion where nei-
ther patients nor the study investigators knew which
study medication was administered. Tiotropium was an
open-label comparator administered via the Handihaler® b.
To maintain blinding, patients taking QD treatments also
took placebo in the evening. Treatment consisted of three
7-day treatment periods, with two intervening 10–14 day
washout periods. A 7–9 day washout period followed the
third treatment period, before a follow-up phone call.
Study withdrawal criteria included COPD exacerbation
(defined as acute worsening of COPD symptoms requiring
treatment beyond study medication or rescue salbutamol,
including antibiotics or systemic corticosteroids, and/
or hospitalisation or emergency treatment), clinically
significant change in laboratory parameters, or elevated
liver chemistry.
Treatment adherence was assessed on Day 7 of each
treatment period using dose counters on the inhaler or
by counting blister doses remaining (tiotropium).
Outcomes and assessments
The primary efficacy endpoint was trough FEV1 on
Day 8, defined as the mean of the FEV1 values obtained
23 and 24 hours after morning dosing on Day 7 of each
treatment period.
The secondary efficacy endpoints were weighted mean
FEV1 over 0–24 hours after morning dosing on Day 7,
and serial FEV1 over 24 hours after morning dosing on
Day 7. Serial spirometry was measured 30 and 5 minutes
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23 and 24 hours after morning dosing.
Additional efficacy endpoints included trough FEV1 at
other time points, weighted mean FEV1 over other time
periods, serial FEV1, trough FVC, weighted mean FVC,
and rescue salbutamol use (mean number of puffs per day
and percentage of rescue-free days). Safety assessments
included incidence of adverse events (AEs), haematology
and clinical chemistry evaluations, incidence of COPD ex-
acerbations, and vital signs.
Plasma and urine samples were collected for pharmaco-
kinetic (PK) analysis. Assessments included area under
concentration-time curve from time 0 to time t (AUC(0-t)),
maximum observed plasma concentration (Cmax), time of
maximum observed plasma concentration (tmax), amount
of drug excreted unchanged in urine, and fraction of dose
excreted unchanged in urine. Accumulation was calcu-
lated using plasma Cmax, plasma AUC using a common
sampling time and amount excreted in urine over the
same time interval on Day 7 versus Day 1.
Spirometry measurements
Measurements for FEV1 and FVC were obtained using
standard spirometry equipment that met or exceeded
the minimal ATS performance recommendations [15].
Spirometry was performed at screening, during a 6-hour
interval on the first day of each treatment period,
and during a 24-hour interval on the last day of each
treatment period. A minimum of three acceptable
spirometry efforts were obtained for FEV1 and FVC,
and the highest measurement was recorded. Pre- and
post-salbutamol spirometry measures at screening deter-
mined patient eligibility.
Sample size determination
The sample size for the population model-based dose
response analysis was determined using the Monte-Carlo
Mapped Power approach for mixed effects [16]. The dose
response from a UMEC dose-ranging study was used
as reference [6]. Using a model-based approach for a
cross-over design study, 16 patients would provide at
least 90% power to show a significant dose response
with 25 patients showing ~95% power. The sample size
was increased to reduce the risk of a false positive result
for the lower UMEC doses – a sample size of 40 patients
per arm would provide <10% chance that lower doses
of UMEC would falsely show a trough FEV1 response
of >100 mL. This number of patients would also provide
approximately 85% power for the comparison of active
treatments with placebo for the primary efficacy endpoint
on Day 8 (ANCOVA analysis). This calculation assumes a
two-sided 5% significance level, a within-patient standard
deviation of 0.170 L (based on Donohue et al. [6]) and a
treatment difference from placebo of 0.130 L. Therefore,approximately 160 patients were recruited to compensate
for a possible 30% dropout rate.
Study population
The primary population for all efficacy and safety analyses
was the modified intent-to-treat (mITT) population,
comprising all patients who were randomised and re-
ceived at least one dose of study medication. The popu-
lation was modified in that outcomes were analysed
based on the actual treatment received rather than the
randomised treatment. The PK population comprised all
patients in the mITT population for whom a PK sample
was obtained and analysed.
Model-based and statistical analysis
Two approaches were used to characterise the relation-
ship between dose and trough FEV1. The first approach
(i.e., the primary analysis) was a model-based analysis
whereby an Emax model was selected from a suite of dose
response shape models to describe the observed trough
FEV1 data as a function of dose. Two key parameters were
estimated from this model - Emax which is an estimate of
the maximum response predicted by the model given the
observed trough FEV1 and ED50 which represents the dose
that achieves 50% of Emax. The modelling approach investi-
gated the impact of the inter-patient variability in trough
FEV1 by examining the influence of patient demographic
and physiologic factors (Additional file 1), and the effect of
QD and BID regimen on the model parameters. Established
model diagnostics were derived [17,18] to demonstrate the
suitability of the chosen dose–response model. Using the
population Emax model, the predictive distribution of
trough FEV1 across treatments was derived by simulating
1000 sets of individual model parameters using the covari-
ance matrix (model uncertainty and random effects) of par-
ameter estimates from the model. Key outputs included
median trough FEV1 (95th percentiles) for QD and BID reg-
imens, the probability of achieving a certain target trough
FEV1 with each dose (adjusted for baseline and placebo),
and median estimates of trough FEV1 (adjusted for
baseline and placebo) across the dose range and by dose
regimen. Both mean baseline FEV1 and period were in-
cluded as covariates.
A Day 8 dataset and a pooled dataset for Days 7 and 8
(post-hoc analysis) were analysed and reported for the
primary efficacy analysis. The rationale for pooling Day
7 and Day 8 was to ensure informative interpretation of
FEV1 response as function of dose, given the repeated
measures for trough FEV1 response within each patient
on different days.
The second approach (also referred to as the secondary
analysis) involved comparison of trough FEV1 at each dose
versus placebo using Analysis of Covariance (ANCOVA).
The change from baseline FEV1 (defined as the mean of
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FEV1 at Day 8 was analysed using a mixed model which
included period baseline FEV1, mean baseline FEV1,
treatment and period as fixed effects, and patient as a
random effect. A similar methodology was used to analyse
weighted mean FEV1 and trough and weighted mean FVC
endpoints. Serial FEV1 was analysed using a similar mixed
model. Sensitivity analyses were conducted to assess the
effect of any interaction of treatment with mean baseline,
period baseline or period by repeating the analysis of
trough FEV1 on Day 8 and adding a variable to indicate
the previous treatment received, removing baselines from
the model or both.
Due to issues with Good Clinical Practice at one in-
vestigator site, a decision was made after unblinding to
re-evaluate the dose–response model and ANCOVA
analysis of trough FEV1 on Day 8, excluding all patients
enrolled at that site.
A Bayesian analysis of the primary endpoint (using the
same covariates as the original mixed- model analysis)
provided the posterior probability distribution of the
treatment difference of each treatment against placebo,Figure 1 Patient disposition and CONSORT flow chart. *1 patient each
(myocardial infarction), and UMEC 31.25 μg BID (dizziness) during active tre
washout. Number of patients (N) for completed treatment period, withdraw
reflects the total number of patients in each treatment group across all thr
during the treatment period, or withdrew during the washout period; two
period’ and not included in the counts and percentages for ‘withdrawn du
BID, twice daily; QD, once daily; UMEC, umeclidinium bromide.i.e. the distribution of the true treatment difference
given the data observed in the study.
Results
Study population
Two hundred and forty-four patients were screened,
163 were randomised (mITT population; Figure 1), and
90% completed the study. Mean treatment compliance
was ≥99.3% across all treatment periods.
Patient demographics and baseline clinical characteristics
are summarised in Table 1. Overall, the study population
had moderate to severely impaired airflow obstruction at
screening, as evident by values for mean post-bronchodilator
FEV1 and FEV1/FVC ratio, and mean post-salbutamol FEV1
and FVC. Across treatment groups, 20–32% of patients
took concomitant COPD medication, most often ICSs
(18–30%) followed by oxygen (4–8%).
Efficacy
Final dose–response model
The physiological Emax model (see Additional file 2) was
optimal in defining the relationship between UMEC dosesin UMEC 15.6 μg QD (acute respiratory failure), UMEC 31.25 μg QD
atment. †1patient in UMEC 125 μg QD (nasopharyngitis) during
n during treatment period, and withdrawn during washout period
ee treatment periods who completed the treatment period, withdrew
patients included in the counts for ‘withdrawn during a treatment
ring a washout period’ actually withdrew during a washout period.
Table 1 Summary of patient population (mITT population),

















American Indian or Alaskan native 1 (<1)
Height (cm)
Mean (SD) 170.2 (9.20)
Weight (kg)
Mean (SD) 79.55 (17.539)
Body mass index (kg/m2)
Mean (SD) 27.36 (5.115)
b.
Parameter Total N = 163
Pre-salbutamol Post-salbutamol
% predicted FEV1 (%)
n 162 163
Mean (SD) 47.0 (12.84) 51.1 (10.16)
FEV1/FVC (%)
n 162 163
Mean (SD) 51.1 (11.65) 52.3 (10.62)
FEV1 (L)
n 162 163
Mean (SD) 1.429 (0.5179) 1.554 (0.4727)
FVC (L)
n 162 163
Mean (SD) 2.803 (0.7948) 3.001 (0.8073)
Reversibility to salbutamol (%)
n 162
Mean (SD) 11.8 (15.31)
Reversibility to salbutamol (mL)
n 162
Mean (SD) 124.2 (212.56)
Mean baseline FEV1 (L)
n 163
Table 1 Summary of patient population (mITT population),
(a) demographic characteristics (b) screening parameters
(Continued)
Mean (SD) 1.408 (0.5282)
Mean baseline FVC (L)
n 163
Mean (SD) 2.763 (0.7920)
Note: mean baseline was defined as the mean of the baseline values from
each treatment period. If one or more values were missing, the mean baseline
was the mean of the non-missing values.
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; mITT,
modified intent-to-treat; SD, standard deviation; UMEC, umeclidinium bromide.
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parameters of the model were estimated with high preci-
sion (coefficient of variation <30%). The ED50 for UMEC
QD dosing was 37 μg (95% CI: 18–57). The predicted Emax
was 0.185 L (95% CI: 0.153, 0.218). Model diagnostics
show suitability of the final model in describing the dose–
response relationship (see Additional file 3). Pooled data
from Day 7 and Day 8 were similar: ED50 of 38 μg and
predicted Emax of 0.156 L.
The model-based simulated median estimates of FEV1
for the QD regimen were plotted together with the ob-
served least square (LS) mean FEV1 treatment differ-
ences (ANCOVA analysis) (Figure 2a). Both methods
showed reasonable agreement in the FEV1 response
with dose with the model-based analysis showing a
clear monotonic dose response. The dose–response
curve suggests that trough FEV1 response did not plat-
eau at the highest dose. Results of the post-hoc model
analysis excluding one investigator site (due to issues
of Good Clinical Practice) were generally consistent
with those for the mITT population (Figure 2b). Similar
trends were also observed for the BID regimen in the mITT
(Figure 2c) and the post-hoc model analysis excluding one
investigator site (Figure 2d).
Simulation based on the final dose–response model
was used to estimate the probability of achieving a par-
ticular response at a given dose (Table 2); this applica-
tion of the model utilised the integrated variability
between- and within-patients across doses to provide a
better insight into the dose–response relationship. Thus,
UMEC 62.5 μg and 125 μg QD had a ≥87% probability
of exceeding the minimum clinically relevant target of
0.100 L trough FEV1 [6] and a ≥77% probability of exceed-
ing a 0.120 L trough FEV1 (Table 2). Based on the total
daily UMEC dose, the model-based analysis suggests that
although there were small numerical differences between
the 31.25 μg QD and 15.6 μg BID dosing regimens,
the probability of exceeding the target response with
the 31.25 μg BID dose is markedly lower than that for






























Parameters Value for day 8 95% CI (%RSE)
Emax (L) 0.185 0.154–0.216 (9)
ED50 (C50–mcg) 37.4 17.8–57.0 (28)
Obs LS Mean (95% CI)























Parameters Value for day 8 95% CI (%RSE)
Emax (L) 0.162 0.103–0.221 (18)
ED50 (C50–mcg) 27.9 19.1–36.7 (16)
Obs LS Mean (95% CI)




































c) Obs LS Mean (95% CI)





























d) Obs LS Mean (95% CI)
Simulated Fitted Model (5th–95th percentiles)
Figure 2 Observed LS mean trough FEV1 and simulated fitted model for UMEC QD and BID regimens. Data are for (a) UMEC QD in the
mITT population, (b) UMEC QD in the mITT population excluding patients from one investigator site, (c) UMEC BID in the mITT population, and
(d) UMEC BID in the mITT population excluding patients from one investigator site. CI, confidence interval; ED50 (C50), dose that yields 50% of
Emax; Emax, maximum predicted FEV1 response; FEV1, forced expiratory volume in 1 second; Obs LS, observed least square; RSE, relative
standard error.
Table 2 Probability of a dose exceeding a target response
(adjusted for placebo) (mITT population)
UMEC dose Probability (%) of exceeding a specified change
from baseline FEV1 at trough (Day 8 dataset)
0.075 L 0.100 L 0.120 L 0.150 L
15.6 μg QD 43 21 11 3
31.25 μg QD 88 74 56 30
62.5 μg QD 95 87 77 52
125 μg QD 99 100 99 92
15.6 μg BID 89 75 59 33
31.25 μg BID 78 60 44 21
BID, twice daily; FEV1, forced expiratory volume in 1 second; QD, once daily;
UMEC, umeclidinium bromide.
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Statistically significant increases in change from baseline
in trough FEV1 over placebo on Day 8 were demonstrated
for all UMEC QD and BID doses (range: 0.101–0.183 L;
p < 0.001 for each comparison); tiotropium (0.101 L;
p < 0.001) was within the range observed for UMEC doses
(Figure 3). Dose ordering was observed across UMEC QD
doses with UMEC 125 μg QD demonstrating the great-
est improvements in trough FEV1. There was some evi-
dence of an interaction of treatment with period baseline
(p = 0.0014) and period (p = 0.0193). The conclusions from
each sensitivity analysis performed to assess the impact
of these interactions were similar to those from the pre-
defined analysis and it was therefore concluded that any




Figure 3 Trough FEV1 (L) on Day 8 (mITT population) for UMEC QD and BID regimens. Data are for (a) mITT population (b) mITT
population excluding patients from one investigator site. BID, twice daily; QD, once daily.
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125 μg QD showed high probabilities (80.1% and 99.8%,
respectively) that the true treatment difference compared
with placebo was greater than 0.100 L for trough FEV1 on
Day 8. The probabilities for 15.6 μg and 31.25 μg QD were
68.2% and 52.0%, respectively. Additionally, UMEC 125 μg
QD showed a 96.8% probability of having a true treatment
difference from placebo of greater than 0.130 L as com-
pared to tiotropium which showed a 15.9% probability.
0–24-hour weighted mean FEV1 on Day 7
Statistically significant improvements in the adjusted mean
changes from baseline in 0–24-hour weighted mean FEV1
over placebo on Day 7 were observed for all UMEC QD
and BID doses and for tiotropium (Table 3). Dose orderingwas observed across QD dose regimens with UMEC
125 μg QD showing the greatest improvements in 0–
24-hour weighted mean FEV1.
Serial FEV1 over 24 hours on Day 7
Serial FEV1 over time on Day 7 demonstrated statistically
significant improvements in the adjusted mean changes
from baseline over placebo for all UMEC doses and tiotro-
pium at all time points (Figure 4). Increases were broadly
consistent across all time points over 24 hours, with no
marked improvement in FEV1 for either BID dose follow-
ing a second UMEC dose at 12 hours. Improvements in
FEV1 over placebo observed at time points over the first
12 hours were maintained over the second 12 hours for
all UMEC QD doses, which is in contrast to an observed






15.6 μg 31.25 μg 62.5 μg 125 μg
N = 60 N = 57 N = 59 N = 60
N 54 56 51 54 56
LS mean (SE) 1.327 (0.018) 1.443 (0.018) 1.445 (0.019) 1.459 (0.018) 1.500 (0.018)
LS mean change (SE) −0.074 (0.018) 0.043 (0.018) 0.045 (0.019) 0.059 (0.018) 0.100 (0.018)
Difference from placebo NA 0.116 0.118 0.132 0.173
95% CI NA (0.072, 0.160) (0.073, 0.163) (0.087, 0.178) (0.129, 0.217)
p-value NA <0.001 <0.001 <0.001 <0.001
0–24-hour UMEC BID Tiotropium
weighted mean FEV1 (L) 15.6 μg 31.25 μg QD 18 μg
N = 56 N = 58 N = 56
N 52 55 53
LS mean (SE) 1.462 (0.018) 1.469 (0.018) 1.484 (0.018)
LS mean change (SE) 0.062 (0.018) 0.068 (0.018) 0.084 (0.018)
Difference from placebo 0.136 0.142 0.157
95% CI (0.091, 0.181) (0.098, 0.186) (0.113, 0.202)
p-value <0.001 <0.001 <0.001
Note: Analysis performed using a mixed model with covariates of trough mean baseline, trough period baseline, treatment and period as fixed effects and subject
as a random effect.
For each treatment period, baseline was defined as the mean of the values obtained 5 and 30 minutes predose on Day 1.
BID, twice daily; CI, confidence interval; FEV1, forced expiratory volume in 1 second; LS, least square; mITT, modified intent-to-treat; NA, not applicable; QD, once
daily; SE, standard error; UMEC, umeclidinium bromide.
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second 12 hours for tiotropium.
Trough FEV1 on Day 7
Statistically significant improvements in the adjusted
mean changes from baseline in trough FEV1 over placebo
on Day 7 were demonstrated for all UMEC QD and BID
doses and for tiotropium (Table 4). The greatest improve-
ment over placebo was observed for UMEC 125 μg QD
(0.120 L). Improvements in trough FEV1 with UMEC
compared with placebo on Day 7 were lower than improve-
ments in trough FEV1 observed on Day 8, although a dose
ordering was maintained with UMEC 125 μg QD providing
the greatest improvement over both days.
0–12-hour and 12–24-hour weighted mean FEV1 on Day 7
Improvements in the adjusted mean changes from baseline
for UMEC QD doses in 12–24-hour weighted mean FEV1
over placebo were generally similar or greater than those
observed for 0–12-hour weighted mean FEV1, indicating
sustained duration of action (Table 5). The ratios of evening
(12–24 hours) to morning (0–12 hours) weighted mean
FEV1 values were approximately 1.0 for all UMEC QD
and BID doses; whereas the ratio for tiotropium was ap-
proximately 0.8 (Table 6). Dose ordering was observed
across the QD regimens with UMEC 125 μg having thelargest effect in both 0–12-hour and 12–24-hour weighted
mean FEV1.
Trough and weighted mean on Day 7
Statistically significant increases in the adjusted mean
changes from baseline in trough and 0–24-hour weighted
mean FVC over placebo on Day 7 were demonstrated for
all UMEC QD and BID doses. Improvements in trough
FVC ranged from 0.128–0.181 L (p ≤ 0.006) for UMEC
doses and 0.126 (p < 0.006) for tiotropium, and im-
provements in 0–24-hour weighted mean FVC ranged
from 0.181–0.247 L (p < 0.001) for UMEC doses and 0.233
(p < 0.001) for tiotropium. Dose ordering was observed
across QD doses for trough FVC and weighted mean
FVC with UMEC 125 μg, showing the largest improve-
ments compared with placebo. FVC values over 24 hours
on Day 7 demonstrated statistically significant differences
compared with placebo for all UMEC QD and BID doses
and tiotropium.
Rescue salbutamol
Dose ordering was observed across UMEC QD doses for
reductions in rescue salbutamol use compared with placebo
which was consistent with the observed FEV1 response:
UMEC 125 μg (0.804 puffs/day), 62.5 μg (0.464 puffs/day),
31.25 μg (0.283 puffs/day), and 15.6 μg (0.254 puffs/day).
Figure 4 Serial FEV1 on Day 7 adjusted treatment differences from baseline. Data are for (a) UMEC QD and tiotropium, and (b) UMEC BID
and tiotropium (mITT population). BID, twice daily; CI, confidence interval; LS, least square; QD once daily; Tio, tiotropium.
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salbutamol use compared with placebo (0.98 puffs/day)
than those observed with UMEC. Increases from baseline
in the percentage of rescue-free days demonstrated dose or-
dering: UMEC 125 μg (15.72%), 62.5 μg (12.50%), 31.25 μg
(9.36%), and 15.6 μg (4.58%). Increases from baseline were
also observed for tiotropium (11.32%).
Pharmacokinetics
The plasma concentration profile for UMEC indicated
that Cmax occurred early (median tmax of 5–15 minutes)
with doses above 31.25 μg QD showing a median tlast of
15 minutes, which was the last collected PK sample.
The lower limit of UMEC quantification (10 pg/mL)
and limited number of samples collected were not suf-
ficient to fully characterise its PK profile; 46% of data
were nonquantifiable. Comparison of UMEC QD and
BID dosing regimens suggested that systemic exposure
(i.e. AUC and Cmax) was higher following QD dosingthan BID dosing for the same total daily dose. Fol-
lowing 7 days repeat dosing, the accumulation ratio
ranged from 1.2 to 1.7 for UMEC systemic exposure.
Approximately 2.2–2.5% of the total dose was excreted
unchanged in urine in 24 hours after QD doses. Urine
excretion of UMEC increased with dose, and the
amount of UMEC excreted in the urine following Day
1 dose was lower than that following Day 7 dose for all
dose levels.
Safety
Overall incidence of AEs was low across treatments
(4–18%). The most frequently reported AEs are shown
in Table 7. Two serious AEs (acute respiratory failure,
UMEC 15.6 μg QD and myocardial infarction UMEC
31.25 μg QD) were reported; neither was fatal or consid-
ered treatment-related by the investigator. Four COPD
exacerbations were reported: one (placebo), two (UMEC
15.6 μg QD), and one (UMEC 125 μg QD).




15.6 μg 31.25 μg 62.5 μg 125 μg
N = 60 N = 60 N = 57 N = 59 N = 60
N 60 59 56 59 60
LS mean (SE) 1.401 (0.019) 1.469 (0.019) 1.482 (0.020) 1.475 (0.019) 1.521 (0.019)
LS mean change (SE) −0.014 (0.019) 0.054 (0.019) 0.067 (0.020) 0.060 (0.019) 0.106 (0.019)
Difference from placebo N/A 0.068 0.081 0.074 0.120
95% CI N/A (0.018, 0.118) (0.030, 0.131) (0.024, 0.124) (0.070, 0.170)
p-value N/A 0.007 0.002 0.004 <0.001
Trough FEV1 (L) UMEC BID Tiotropium QD
15.6 μg 31.25 μg 18 μg
N = 56 N = 58 N = 56
N 55 57 56
LS mean (SE) 1.484 (0.020) 1.500 (0.020) 1.493 (0.020)
LS mean change (SE) 0.069 (0.020) 0.085 (0.020) 0.078 (0.020)
Difference from placebo 0.083 0.099 0.092
95% CI (0.032, 0.134) (0.048, 0.149) (0.041, 0.142)
p-value 0.001 <0.001 <0.001
Analysis performed using a mixed model with covariates of period baseline, mean baseline, treatment and period as fixed effects and patient as a random effect;
for each treatment period, baseline was defined as the mean of the values obtained 5 and 30 minutes pre-dose on Day 1 and trough FEV1 is calculated from the
FEV1 values obtained 23 and 24 hours after the Day 6 morning dose.
BID, twice daily; CI, confidence interval; FEV1, forced expiratory volume in 1 second; LS, least square; mITT, modified intent-to-treat; N/A, not applicable; QD, once
daily; SE, standard error; UMEC, umeclidinium bromide.
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http://www.biomedcentral.com/1471-2466/14/2UMEC was generally well tolerated at all doses, with
no apparent dose-related changes in vital signs. Mean
absolute values on Day 7 were similar across treatments
for all clinical chemistry and haematology assessments
except creatine kinase, which was elevated compared with
placebo for UMEC 31.25 μg QD and BID and UMEC
62.5 μg QD. Most patients across all treatments had creat-
ine kinase values within the normal range at baseline and
any post-baseline assessment. The pattern of out of range
values across UMEC QD treatments did not appear to be
related to dose (8%, 13%, 9%, and 3% for the 15.6 μg,
31.25 μg, 62.5 μg, and 125 μg QD treatments, respectively,
and 5% for placebo).
Discussion
The current study demonstrated that QD dosing with
UMEC provided statistically and clinically significant
improvements in lung function over 24 hours. These
results extend the findings from two previous dose-
ranging studies [6,8] by demonstrating a dose ordering
over a range of UMEC 15.6 to 125 μg QD and further
substantiating that UMEC is efficacious when administered
QD. In addition, trough FEV1 results for the overlapping
doses of UMEC 125 μg QD and UMEC 62.5 μg QD from
this study were similar to that observed in the previous
dose-ranging studies (UMEC 125 μg QD: 0.147 L [95% CI:0.077, 0.216] [6] and 0.159 L [95% CI: 0.088, 0.229] [8] and
UMEC 62.5 μg QD: 0.128 L [95% CI: 0.060, 0.196] [6]).
Consistent with published dose–response models for
bronchodilators [19,20], a population physiological Emax
model characterised the relationship between UMEC
dose and trough FEV1 on Day 8. A clear monotonic
UMEC dose response was observed with dose order-
ing from the lowest (15.6 μg) to highest dose (125 μg).
The maximum dose (125 μg UMEC QD) equated to
approximately 3.4-fold ED50 of 37 μg estimated in this
study. The trough FEV1 response for UMEC 125 μg QD
(0.183 L) was near the maximum predicted response
from the model (0.185 L) and was similar to the trough
FEV1 response observed in the previous dose-ranging
studies in patients with COPD, which ranged from
0.147 to 0.159 L [6,8].
A dose ordering was observed across UMEC QD dosing
regimens with the UMEC 125 μg QD dose demonstrating
the greatest improvement in lung function measurements
compared with the lower QD doses. This pattern was
further supported by Bayesian analysis of trough FEV1.
Although all UMEC QD doses exhibited greater im-
provements in serial FEV1 measures compared with pla-
cebo at Day 7, UMEC 125 μg QD maintained greater
increases from baseline in FEV1 across serial time points
over 24 hours compared with the other QD doses.
Table 5 0–12-hour and 12–24-hour weighted mean FEV1 (L) on Day 7, (a) morning and (b) evening dose (mITT population)
a.
Morning dose: UMEC QD
0–12-hour Placebo 15.6 μg 31.25 μg 62.5 μg 125 μg
weighted mean FEV1 (L) N = 60 N = 60 N = 57 N = 59 N = 60
N 54 58 52 56 56
LS mean (SE) 1.353 (0.019) 1.467 (0.019) 1.478 (0.020) 1.481 (0.019) 1.526 (0.019)
LS mean change (SE) −0.046 (0.019) 0.068 (0.019) 0.078 (0.020) 0.082 (0.019) 0.126 (0.019)
Difference from placebo N/A 0.114 0.124 0.128 0.172
95% CI N/A (0.066, 0.161) (0.075, 0.173) (0.079, 0.177) (0.124, 0.220)
p-value N/A <0.001 <0.001 <0.001 <0.001
Morning dose: UMEC BID Tiotropium QD
0–12-hour 15.6 μg 31.25 μg 18 μg
weighted mean FEV1 (L) N = 56 N = 58 N = 56
N 52 55 53
LS mean (SE) 1.483 (0.020) 1.483 (0.019) 1.530 (0.020)
LS mean change (SE) 0.084 (0.020) 0.084 (0.019) 0.130 (0.020)
Difference from placebo 0.130 0.130 0.176
95% CI (0.081, 0.178) (0.081, 0.178) (0.128, 0.224)





12–24-hour 15.6 μg 31.25 μg 62.5 μg 125 μg
weighted mean FEV1 (L) N = 60 N = 60 N = 57 N = 59 N = 60
n 54 56 52 54 56
LS mean (SE) 1.298 (0.020) 1.410 (0.020) 1.410 (0.020) 1.433 (0.020) 1.470 (0.020)
LS mean change (SE) −0.103 (0.020) 0.010 (0.020) 0.010 (0.020) 0.032 (0.020) 0.069 (0.020)
Difference from placebo N/A 0.112 0.112 0.135 0.172
95% CI N/A (0.064, 0.160) (0.063, 0.162) (0.085, 0.184) (0.123, 0.221)
p-value N/A <0.001 <0.001 <0.001 <0.001
Evening dose: UMEC BID Tiotropium QD
12–24-hour 15.6 μg 31.25 μg 18 μg
weighted mean FEV1 (L) N = 56 N = 58 N = 56
n 52 55 53
LS mean (SE) 1.440 (0.020) 1.450 (0.020) 1.437 (0.020)
LS mean change (SE) 0.039 (0.020) 0.050 (0.020) 0.036 (0.020)
Difference from placebo 0.141 0.152 0.138
95% CI (0.092, 0.191) (0.103, 0.201) (0.090, 0.187)
p-value <0.001 <0.001 <0.001
Church et al. BMC Pulmonary Medicine 2014, 14:2 Page 11 of 14
http://www.biomedcentral.com/1471-2466/14/2Interestingly, greater improvements in trough FEV1
were observed on Day 8 compared to improvements
observed on Day 7. This may be explained by the time
of drug administration. Measurements on Days 7 and 8
were taken 23 and 24 hours after dosing; however, only
dosing before the Day 8 measures was observed by study
staff. Furthermore, patients were required to stay over-
night between Days 7 and 8. Both of these factors mayexplain the differences observed in trough FEV1 across
the two study days. Modelling of the pooled Day 7 and 8
data provided similar results to those on Day 8 only, and
the ANCOVA results on Day 7 supported those on Day 8.
Although patients with COPD are known to change their
responsiveness to treatment over time, individual hetero-
geneity in response to treatment was not examined during
this study, which may be viewed as a limitation. Individual
Table 6 Change from baseline in weighted mean FEV1 (L) difference in treatment effect compared between 12–24-hour
and 0–12-hour at Day 7 (mITT population)
Placebo
UMEC QD
15.6 μg 31.25 μg 62.5 μg 125 μg
N = 60 N = 60 N = 57 N = 59 N = 60
N 54 58 53 56 56
Column vs. placebo N/A 0.018 −0.007 0.021 0.010
Absolute difference
95% CI N/A (−0.040, 0.076) (−0.067, 0.053) (−0.038, 0.080) (−0.048, 0.069)
Ratio* N/A 1.176 0.943 1.162 1.059
UMEC BID Tiotropium QD
15.6 μg 31.25 μg 18 μg
N = 56 N = 58 N = 56
N 52 55 53
Column vs. placebo 0.019 0.028 −0.036
Absolute difference
95% CI (−0.041, 0.078) (−0.030, 0.087) (−0.095, 0.023)
Ratio* 1.147 1.215 0.793
*Relative to 0–12-hour weighted mean FEV1.
Absolute differences >0 indicate a larger treatment effect between 12–24 hours; analysis performed using a mixed model with covariates trough mean baseline,
trough period baseline, treatment, period, time and time by treatment interaction as fixed effects and subject as a random effect.
Note: The column versus placebo difference was calculated as the difference in change from baseline in weighted mean FEV1 between active and placebo at
12–24 hours minus the difference in change from baseline in weighted mean FEV1 between active and placebo at 0–12 hours. The ratio is the difference in
change from baseline in weighted mean FEV1 between active and placebo at 12–24 hours divided by the difference in change from baseline in weighted mean
FEV1 between active and placebo at 0–12 hours.
BID, twice daily; CI, confidence interval; N/A, not applicable; QD, once daily; UMEC, umeclidinium bromide.
Table 7 On-treatment adverse events reported by ≥3% of
patients within any treatment group (mITT population)
Number (%) of patients
Preferred term UMEC QD
Placebo 15.6 μg 31.25 μg 62.5 μg 125 μg
N = 60 N = 60 N = 57 N = 59 N = 60
Headache 2 (3) 1 (2) 0 0 3 (5)
Nasopharyngitis 0 1 (2) 0 0 1 (2)
Dysgeusia 0 1 (2) 0 0 2 (3)
Sinusitis 0 0 0 0 2 (3)
Preferred term UMEC BID Tiotropium
15.6 μg 31.25 μg QD 18 μg
N = 56 N = 58 N = 56
Headache 4 (7) 1 (2) 0
Nasopharyngitis 0 0 2 (4)
Dysgeusia 0 0 0
Sinusitis 0 0 0
Cut-off of ≥3% was based on percentage after rounding; on-treatment AEs
were defined as AEs with onset within the period beginning with the first day
of study drug administration through the day after the last day of study
drug administration.
BID, twice daily; mITT, modified intent-to-treat; QD, once daily; UMEC,
umeclidinium bromide.
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of the study only because the study was small; however,
the analysis was adjusted for the effect of patient, treat-
ment and period.
The effects of UMEC QD versus BID dosing were also
examined and BID regimens demonstrated small increases
in the difference from placebo in some measures over
QD regimens of the same total daily dose. Our study
was not powered for formal comparisons between QD
and BID doses. Given the small magnitude of improve-
ment observed with BID dosing, it is considered un-
likely to translate into a clinically significant benefit in
efficacy. Improvements in serial FEV1 from placebo over
the first 12 hours were maintained at time points over
the second 12 hours for all UMEC QD doses, suggesting
that QD dosing is supported for UMEC. Additionally, the
ratios of evening (12–24-hour) to morning (0–12-hour)
weighted mean FEV1 values were approximately 1.0 for all
QD doses indicating that the 24-hour duration of effect is
an intrinsic property of UMEC rather than being of a
dose-related nature. The model-based analysis did not find
dose regimen (QD versus BID) to be an important factor
influencing dose response, which is also consistent with the
previous study results [6]. This finding is not unexpected
given that preclinical UMEC data demonstrated slow off-
rate receptor kinetics in in-vitro human M3 receptor and
Church et al. BMC Pulmonary Medicine 2014, 14:2 Page 13 of 14
http://www.biomedcentral.com/1471-2466/14/2bronchial tissue, and support a QD regimen [21]. It is
noteworthy that the BID regimen showed small numerical
increases in FEV1 values compared with those following
QD and this finding is reflected in the probability values
for 15.6 μg BID versus 31.25 μg OD. These numerical
differences in FEV1 response between regimens are
generally accounted for by the model-based analysis that
integrated the variability estimates between- and within-
patient across all doses [19]. Plausible reasons for the
marked lower probability estimates at 31.25 μg BID
compared with the 62.5 μg OD regimen may include
study design factors, namely imbalance in patient dose
allocation due to the incomplete block study design, or
possible clinical under-performance of the 31.25 μg BID
formulation.
The LAMA tiotropium was used as an active comparator
in this study as it is a well-established medication for
the treatment of COPD [22]. Although the observed im-
provement in trough FEV1 over placebo with tiotropium
was within the range of those observed with UMEC
doses, tiotropium was at the lower end of the range.
Nearly all UMEC QD and BID doses demonstrated im-
provements over placebo in trough FEV1 on Day 8
(range: 0.101–0.183 L) that were numerically similar to
or greater than tiotropium (0.101 L). However, trough
FEV1 does not convey the full picture of bronchodila-
tion offered to patients, and thus the 24-hour weighted
mean and 24-hour serial FEV1 profiles were also evalu-
ated. The 24-hour weighted mean and 24-hour serial
FEV1 profiles showed UMEC doses of 62.5 and 125 μg
were the most similar in efficacy to tiotropium, with the
bronchodilator effect of the 62.5 μg dose generally less
and the effect of the 125 μg dose generally greater than
that of tiotropium over time. These data suggest that
UMEC 125 μg and UMEC 62.5 μg would be appropriate
doses to use in future clinical studies to further assess
efficacy and safety of UMEC in COPD patients.
No assessments of COPD-related symptoms were
included in this study. However, rescue salbutamol on
an as-needed basis for breakthrough symptoms provided
a secondary marker of symptom control. Treatment with
UMEC reduced rescue salbutamol use compared with pla-
cebo at all doses and a dose ordering of reduction in salbu-
tamol use was observed for UMEC QD doses, with UMEC
125 μg QD doses showing the greatest improvement. Res-
cue salbutamol use data are consistent with the observed
improvements in lung function (i.e. the greatest reduction in
use was observed with UMEC 125 μg QD, which had the
greatest improvement in lung function parameters). Inter-
estingly, the greatest reduction in salbutamol occurred with
tiotropium. This may be due to the design of the study in
that tiotropium was administered in an open-label fashion.
This was the first study to examine the PK of low-
dose UMEC (15.6 μg and 31.25 μg QD and the BIDdosing regimen) in patients with COPD. In spite of the
large percentage of non-quantifiable data, increased
UMEC systemic exposure (in terms of AUC and Cmax)
was seen with lower doses. Median Cmax occurred early
for all UMEC doses. Systemic exposure was higher fol-
lowing QD dosing than BID dosing for the same total
daily dose. Cross-study comparison of the steady-state
data with previous studies of UMEC 62.5 μg to 1000 μg
QD suggest that systemic exposure of UMEC was within
the expected range [6,8].
The safety profile was comparable between treatment
groups. Overall, AEs were higher with UMEC 125 μg QD
dosing (18%) than placebo or the other active treatments;
however, the individual AEs observed with the UMEC
125 μg QD consisted of reports of sinusitis, dysgeusia,
nasopharyngitis, and headache. Headache was the most
common AE across all treatments and did not appear
related to active treatment. Although the AEs of naso-
pharyngitis, dysgeusia, and sinusitis could potentially be
topical effects of LAMA treatment, these events occurred
only with UMEC 15.6 μg and 125 μg QD dosing and so
did not appear to be dose-related. Overall, UMEC was
well tolerated across all dose regimens.
Conclusion
In summary, UMEC QD statistically and clinically im-
proved lung function over 24 hours in a study population
that was representative of patients with moderate-to-severe
COPD. UMEC was generally well tolerated, with dose-
ordering over UMEC QD doses of 125–15.6 μg observed.
Based on results from this study, the 62.5 and 125 μg
doses were considered appropriate for subsequent cli-
nical investigation.
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